To validate the observed effects in different cell types, we knocked out Mfsd7c in human breast cancer MCF7 cells and human embryonic kidney 293T cells using CRISPR-Cas9 genome editing (Supplementary Fig. 6a). The gene discussed is FLVCR2; the disease is breast carcinoma.